| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Ulf Wiinberg is Director at AGEN and has filed Form 4s across 2 companies. Ulf Wiinberg's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.1M at current prices.
Historically, Ulf Wiinberg's trades have earned a middling insider score of 52/100 across 3 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of -2.3%.
The biggest single holding is AGEN (~$828K) as Director. Net of sales, the AGEN filings show accumulation of 55,000 shares.
Ulf Wiinberg has 67 Form 4 filings on record from May 2016 to September 2026, across 2 companies: Director at MiNK Therapeutics (INKT), 2022–2026; Director at Agenus (AGEN), 2016–2024.
The 74 reported transactions were 50 option or other derivative awards, 17 stock awards, 4 open-market purchases and 3 option exercises.
Counted by filing, the open-market trades come to 3 purchases worth about $235K and no sales.
The largest open-market purchase was 30,000 shares of AGEN at an average $6.29 on September 6, 2016, about $189K.